Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating income | -$26.8M | -$72.3M |
| Net income | -$26.5M | -$70.0M |
| EPS (diluted) | -$37.05 | -$111.91 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$23.7M | -$71.6M |
| Capital expenditures | $0.00 | $24.0K |
| Free cash flow | -$23.7M | -$71.6M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $53.1M | $21.8M |
| Total assets | $55.5M | $153M |
| Total liabilities | $4.72M | $9.16M |
| Shareholders' equity | -$48.5M | -$121M |
| Retained earnings | -$49.2M | -$123M |
| Shares (wtd avg diluted) | 737K | 745K |
Every figure is extracted from Veradermics, Inc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.